Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 17/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719603 | 0.89 | AGTR2 (0.80) | AGTR2CYP2C9CYP2B6AGTR1 | |
| SCHEMBL1718507 | 0.86 | AGTR2 (1.00) | AGTR2CYP2C9CYP2B6AGTR1 | |
| SCHEMBL1718923 | 0.85 | AGTR2 (0.75) | AGTR2CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL1719714 | 0.85 | AGTR2 (0.81) | AGTR2CYP2C9CYP2B6AGTR1 | |
| SCHEMBL29106461 | 0.85 | AGTR2 (0.84) | AGTR2CYP3A4CYP2C9CYP2B6AGTR1 | |
| SCHEMBL1718889 | 0.85 | AGTR2 (0.73) | AGTR2CYP3A4 | |
| SCHEMBL1718884 | 0.82 | AGTR2 (0.85) | AGTR2CYP2C9CYP2B6AGTR1 | |
| SCHEMBL1720280 | 0.81 | AGTR2 (0.74) | AGTR2CYP2C9CYP2B6AGTR1 | |
| SCHEMBL1718272 | 0.81 | AGTR2 (0.73) | AGTR2CYP2C9CYP2B6AGTR1 | |
| SCHEMBL1719217 | 0.81 | AGTR2 (0.73) | AGTR2CYP2C9CYP2B6AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869023-B1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| US-8080571-B2 | Tricyclic angiotensin II agonists | VICORE PHARMA AB (SE) | 2011-12-20 | — | — | US | disclosed |
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | VICORE PHARMA AB (SE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | AGTR2 1/4885CYP3A4 354/4885CYP2C9 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.